Effects of N-acetyl cysteine on serum lipoprotein (a) and proteinuria in type 2 diabetic patients

Journal of Nephropathology

Volumn 2, Issue 1, 2013, Pages 61-66

  Rouhi, Hamid ^a   Ganji, Forouzan ^a  

^a SHAHREKORD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetic nephropathy; Lipoprotein (a); N acetyl cysteine (NAC)

Indexed keywords

EID: 84874713788     PISSN: 22518363     EISSN: 22518819     Source Type: Journal    
DOI: 10.5812/nephropathol.8940     Document Type: Article

References (31)

1. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164-76.
2. Song KH, Ko SH, Kim HW, Ahn YB, Lee JM, Son HS, et al. Prospective study of lipoprotein(a) as a risk factor for deteriorating renal function in type 2 diabetic patients with overt proteinuria. Diabetes Care. 2005;28(7):1718-23.
3. Nasri H, Baradaran A. Association of serum lipoprotein(a) with ultrasonographically determined early atherosclerotic changes in the carotid and femoral arteries in kidney transplanted patients. Transplant Proc. 2004;36(9):2683-6.
4. Nasri H, Baradaran A. Association of Early Atherosclerotic Vascular Changes with Serum Lipoprotein (a) in Predialysis Chronic Renal Failure and Maintenance Hemodialysis Patients. Saudi J Kidney Dis Transpl. 2005;16:154-60.
5. Baradaran A, Nasri H. Association of serum lipoprotein (a) with left ventricular hypertrophy in hemodialysis patients. Indian J Nephrol. 2004;14(2):41-5. Available at:http://www.indianjnephrol.org/.
6. Lakhotia M, Gehlot RS, Jain P, Sharma S, Singh M. Lp(a) in type II diabetic subjects in relation to diabetic microvascular complications. IACM. 2003;4(4):304-7. Available at:http://www.google.com/url?sa=t.
7. Hernández C, Chacón P, García-Pascual L, Simó R. Differential influence of LDL cholesterol and triglycerides on lipoprotein(a) concentrations in diabetic patients. Diabetes Care. 2001;24(2):350-5.
8. Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis. 1996;27(1):1-25.
9. Nasri H. Association of serum lipoprotein (a) with hypertension in diabetic patients. Saudi J Kidney Dis Transpl. 2008;19(3):420-7.
10. Fulghesu AM, Ciampelli M, Muzj G, Belosi C, Selvaggi L, Ayala GF, Lanzone A. N-acetyl-cysteine treatment improves insulin sensitivity in women with poly-cystic ovary syndrome. Fertil Steril. 2002;77:1128-35.
11. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with endstage renal failure: a randomized, controlled trial. Circulation. 2003;107(7):992-5.
12. Trimarchi H, Mongitore MR, Baglioni P, Forrester M, Freixas EA, Schropp M, et al. N-acetylcysteine reduces malondialdehyde levels in chronic hemodialysis patients: a pilot study. Clin Nephrol. 2003;59(6):441-6.
13. Gavish D, Breslow JL. Lipoprotein(a) reduction by Nacetylcysteine. Lancet. 1991;337:203-4.
14. Kroon AA, Demacker PN, Stalenhoef AF. N-acetylcysteine and serum concentrations of lipoprotein(a). J Intern Med. 1991;239(6):519-26.
15. Nakagawa H, Kida Y, Sakamoto K, Haneda M, Kikkawa R. Relationship between the stage of diabetic nephropathy and serum lipoprotein (a) concentrations- -influence of hypoproteinemia. Nihon Jinzo Gakkai Shi. 1996;38(11):513-8.
16. Kumari SJ, Jayarma N, Vincet L, Venkatesh T. Serum Lp(a) in diabetices with and without evidence of nephropathy. Indian Jurnal of Clinical Biochemistry. 2002;17(1):45-8.
17. Jenkins AJ, Best JD. The role of lipoprotein(a) in the vascular complications of diabetes mellitus. J Intern Med. 1995;237(4):359-65.
18. Hirano T. Lipoprotein abnormalities in diabetic nephropathy. Kidney Int Suppl. 1999;71:S22-4.
19. Erem C, Değer O, Bostan M, Orem A, Sönmez M, Ulusoy S, et al. Plasma lipoprotein (a) levels in Turkish NIDDM patients with and without vascular diabetic complications. Acta Cardiol. 1999;54(4):203-7.
20. Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med. 1991;324(26):1852-7.
21. Stalenhoef AF, Kroon AA, Demacker PN. N-acetylcysteine and lipoprotein. Lancet. 1991;337(8739):491.
22. Scanu AM. N-acetylcysteine and immunoreactivity of lipoprotein(a). Lancet. 1991;337(8750):1159.
23. Scanu AM, Pfaffinger D, Fless GM, Makino K, Eisenbart J, Hinman J. Attenuation of immunologic reactivity of lipoprotein(a) by thiols and cysteine-containing compounds. Structural implications. Arterioscler Thromb. 1992;12(4):424-9.
24. Rath M, Pauling L. Lipoprotein(a) Reduction by Ascorbate. Journal of Orthomolecular Medicine. 1992;7:81-2. Available at:http://www4ger.dr-rath-foundat.
25. Wiklund O, Fager G, Andersson A, Lundstam U, Masson P, Hultberg B. N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels. Atherosclerosis. 1996;119(1):99-106.
26. Renke M, Tylicki L, Rutkowski P, Larczyński W, Aleksandrowicz E, Lysiak-Szydłowsk W, et al. The effect ofN-acetylcysteine on proteinuria and markers of tubular injury in non-diabetic patients with chronic kidney disease. A placebo-controlled, randomized, open, cross-over study. Kidney Blood Press Res. 2008;31(6):404-10.
27. Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics with Proteinuria. Available at:http://clinicaltrials. gov/show.
28. Krug S, Zhang Y, Mori TA, Croft KD, Vickers JJ, Langton LK, et al. N-Acetylcysteine prevents but does not reverse dexamethasone-induced hypertension. Clin Exp Pharmacol Physiol. 2008;35(8):979-81.
29. Martina V, Masha A, Gigliardi VR, Brocato L, Manzato E, Berchio A, et al. Long-term N-acetylcysteine and Larginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Diabetes Care. 2008;31(5):940-4.
30. Hsu CC, Huang CN, Hung YC, Yin MC. Five cysteinecontaining compounds have antioxidative activity in Balb/ cA mice. J Nutr. 2004;134(1):149-52.
31. Franceschini G, Werba JP, Safa O, Gikalov I, Sirtori CR. Dose-related increase of HDL-cholesterol levels after Nacetylcysteine in man. Pharmacol Res. 1993;28(3):213-8.